Still getting better as they speak: strength that has continued or built past the reported period, tied to named live dr
The model's full reasoning — Q3 2022 call → NOWe need answer YES or NO only. Need analyze transcript. Question asks whether management conveys positive momentum continued/strengthened beyond reported period (Q3 2022) tied to named already-live driver. Need find in transcript. We have earnings call Nov 9 2022. Discuss OASIS Phase 1/2a data, extension study interim data, plans. Financial runway. They report positive data but any continuing strength beyond period? They mention "We will continue to follow eight patients in Extension Study" and expect report final data Q1 2023. They are actively planning Phase 2. But not business activity like orders/sales. This is clinical stage biotech. Positive momentum might be clinical trial progress. But question asks "business's positive momentum HAS CONTINUED OR STRENGTHENED BEYOND THE PERIOD BEING REPORTED" and "named, already-live driver." Management describes OASIS data from trials, extension study interim data as of Oct 27, 2022 (after quarter ended Sep 30). They say "we are very encouraged by durability data emerging" and "data gives us very high confidence to move ahead" but do they describe actual activity continuing? They mention patients still being monitored in Extension Study, data cut Oct 27. That is after period, but that's clinical trial follow-up, not business momentum like sales. Also financial runway into 2024. They don't mention revenue. They might mention "SCS Microinjector commercially accepted following launch of XIPERE" as driver but not tied to continuing strength beyond quarter? Need see. Question needs YES only if management's own words convey both: strength extends past reported period AND named live driver. This is likely NO because no business momentum in terms of sales. Also they are clinical stage, no product revenue. But perhaps they have XIPERE commercialization partner? They mention XIPERE launch, but not in context of continuing strength. They say "Delivery of small molecules via SCS Microinjector has been commercially accepted by retina physicians following launch of XIPERE." That is a driver but not necessarily tied to Q3 momentum beyond period. Also they report positive clinical data and extension study ongoing. But continuation is clinical trial data reading, not business activity.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| CW | Curtiss-Wright Corporation | Q1 2024 | 2024-05-02 | B+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CNA | CNA Financial Corporation | Q4 2022 | 2023-02-06 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHUY | Chuy's Holdings, Inc. | Q3 2022 | 2022-11-05 | C+ |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| WHF | WhiteHorse Finance, Inc. | Q1 2022 | 2022-05-10 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| WRB | W. R. Berkley Corporation | Q1 2022 | 2022-04-26 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| NGVT | Ingevity Corporation | Q4 2021 | 2022-02-25 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| PRI | Primerica, Inc. | Q3 2016 | 2016-11-10 | B+ |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GEO | The GEO Group, Inc. | Q2 2016 | 2016-08-02 | B+ |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
GES · Q1 2017 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the period being reported, tied to a named, already-live driver. YES Management describes continued strength in Europe retail comps into Q2 ("up in the low double digits... maintaining the strong momentum we have seen since the second half of last year") and ties it to a specific, live driver: improved traffic and conversion rates. The wholesale order book also finished up 3%, confirming 3% growth in orders already placed. Product improvements are explicitly named as the underlying driver ("we are having a more comprehensive collection... improve our comps by generating more traffic... improve the product that we are offering"). This meets both criteria for continuation beyond the reported period tied to a named live driver.
ILMN · Q1 2018 → YESThe question is about whether management conveys that the business's positive momentum has continued or strengthened beyond the reported period, tied to a named, already-live driver. YES Management describes the sequencing consumables business as having "very exciting" trajectory and "tremendous momentum" that is "still in place" into the rest of 2018, explicitly tied to observed drivers already generating revenue in Q1 (NovaSeq, NextSeq, microarray, consumer genomics, oncology) and 2018 activity such as "approaching 100 orders" for iSeq and "growing interest" in single-cell research. They raise guidance based on these continuing trends rather than forecasts alone, confirming the strength has extended past the reported period through live business activity.
WRB · Q1 2022 → YESThe question is: Does management convey that the business's positive momentum HAS CONTINUED OR STRENGTHENED BEYOND THE PERIOD BEING REPORTED, and tie that to at least one NAMED, ALREADY-LIVE driver? ...NO The transcript shows management expressing confidence in Q1 momentum (especially March and later-quarter submissions in specialty/E&S) and noting that "every day that we are writing business in 2022 that goes by" is positive, but this is framed as ongoing daily activity within the current year rather than observed strength beyond the 2022 Q1 close. The call is April 25, 2022, so any post-quarter commentary is limited to general market trajectory comments without specific post-period-end activity metrics.